收盘价:Aug 17, 16:00:00 GMT-4
盘后:Aug 17, 17:03:21 GMT-4
No Data Yet
Kahn Swick & Foti opened an investigation into Vertex Pharmaceuticals' proposed $85-a-share cash acquisition of Crinetics Pharmaceuticals, questioning whether the price and sale process adequately compensate shareholders.
CRISPR Therapeutics reported a narrower-than-expected Q2 loss and revenue beat as Casgevy sales surged 151% year over year.
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash, paying a 102 percent premium to build an endocrinology franchise.
Vertex Pharmaceuticals Inc 'in P/E oranı 30.5687 'dir
Dr. Reshma Kewalramani 2018 'den beri şirketle birlikte olan Vertex Pharmaceuticals Inc 'in President 'ıdır.
VRTX 'in mevcut fiyatı $515.55 'dir, son işlem günde 0.01% 下降 etti.
Vertex Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Vertex Pharmaceuticals Inc 'in mevcut piyasa değerlemesi $130.8B 'dir
Wall Street analistlerine göre, 29 analist Vertex Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 8 güçlü al, 17 al, 13 tut, 0 sat ve 8 güçlü sat içermektedir